Status
Conditions
Treatments
About
To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.
Full description
In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. No intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. The study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. Data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. The patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
2,500 participants in 1 patient group
Loading...
Central trial contact
Maria Bokarewa, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal